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Abstract
Urticaria is a common process. The true incidence is not known; it is believed 
that between 15 and 25% of the population may suffer at some point in his life. 
Acute urticaria has a prevalence of 20% and the chronic form 0.5–1%. Urticaria 
is a disease that affects the skin and mucosa, characterized by the presence of 
hives. It occurs as a localized intracutaneous edema circled and an area of redness 
(erythema), which is typically itchy. There are histaminergic foods and drugs that 
worsen the prognosis of the disease. Foods which rely on aging to taste nice are 
always presumed to be high in histamine (chocolate, yogurt, seafood, strawber-
ries, etc.) and drugs like nonsteroidal anti-inflammatory drugs. For diagnosis 
we have several tools (urticarial activity score, chronic urticaria quality-of-life 
questionnaire (CU-Q2oL), urticaria control test, etc., among which the most 
useful, simple, and cost-effective is the clinic history). The treatment of choice 
are antihistamines, from a daily tablet up to four tablets as maximum dose. 
Corticosteroids are excluded to exacerbations and must be prescribed in short 
guideline (maximum 10 days) without progressive decrease. Severe forms of 
urticaria resistant to treatment with antihistamines are treated with biological 
agents like omalizumab.
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1. Introduction
The interest in making this chapter was to explain the pathology of chronic 
urticaria as prevalent and its high morbidity.
We often see this problem in our primary care consultations and emergency 
services, so we consider its important to make a chapter about urticaria.
The current version of the EAACI/GA2LEN/EDF/WAO urticaria guideline from 
2018 contains new aspects about diagnosis and treatment.
At the end of the chapter, we show a series of cases treated in our practice 
(observed in a Juan Ramon Jimenez’s dermatology room in Huelva, Spain), expos-
ing results obtained with the different forms of treatment (Figure 1).
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2. Epidemiology
Urticaria is a common process. Although the true incidence is not known, it is 
believed that between 15 and 25% of the population may suffer at some point in 
his life. Acute urticaria has a prevalence of 20% and the chronic form 0.5–1% [1]. 
Age, race, sex, occupation, geographical region, and the season of the year may be 
implicated in urticaria and angioedema. The majority of acute episodes are due to 
adverse reactions to medications or food or, in children, to viral diseases.
Spontaneous chronic urticaria represents about 70% of all chronic hives and 
may persist for several years. Patients with chronic urticaria often describe a 
decrease in the quality of life because of itching and may have alterations of sleep, 
fatigue, social isolation, or emotional disorders (Figures 2–4).
2.1 Physiopathology
Urticaria is a disease that affects the skin and mucosa, characterized by the pres-
ence of hives. It is a localized intracutaneous edema that circled an area of redness 
(erythema), which is typically itchy. Individual hives can persist from 30 minutes 
to 36 hours and can measure from only 1 millimeter up to 15–20 cm in diameter, 
named giant hives [3]. Increased dilation and permeability of blood vessels that 
characterize the hives are present in the superficial dermis and undertake the 
venous plexus located there (Figure 5). It is rare and it may occur with concomitant 
angioedema.
Another similar entity is angioedema, with a similar mechanism as urticaria 
[4], but the pathology is located in the deep dermis and subcutaneous tissue, and 
swelling is the main manifestation. The skin may be normal or erythematous. There 
is less itching, but it can cause pain or burning sensation. The mouth, lips, eyes, 
throat, feet, and hands are most commonly affected (Figures 6 and 7). When angio-
edema affects the throat, it can be life-threatening, because there is interference in 
Figure 1. 
Chronic urticaria.
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breathing. It is caused by an allergic reaction, sometimes by a hereditary condition 
(hereditary angioedema), but normally we do not know the cause [4].
2.2 Food histamine liberator
Foods that require a ripening process to achieve a better taste are presumed 
to have a high histamine content. In the same way as foods that are made during 
fermentation. These include de following [5] (Table 1).
Figure 2. 
Epidemiology of chronic urticaria in United States.
Figure 3. 
Epidemiology of chronic urticaria in Australia.
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The Spanish society of diamine oxidase (DAO) states on their website that the 
following food histamine liberators:
• Alcohol, citrus fruits, strawberries, pineapple, kiwi, tomato sauce, seafood, 
chocolate, fish, mushrooms, pig, cereals, and egg white.
• Some food additives such as glutamate, benzoate, several colorants (yellow 
E-102 and E-110, E-124, amaranth E-123), sulfites, and nitrites can release 
endogenous histamine.
The department for dermatology in Bonn’s paper lists the following foods as 
being capable of releasing endogenous histamine (Table 2).
2.3 Pathogenesis
The mast cell is the main effector cell in urticaria and angioedema. Cutaneous 
mast cells attach to fibronectin and laminin through the integrin beta1 of Very Late 
Figure 4. 
Prevalence of chronic urticaria.
Figure 5. 
Urticaria. Picture with histological findings.
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Antigen (VLA), VLA-3, VLA-4, and VLA-5 activation and vitronectin through alfa1 
and beta3 integrin [6].
Once activated, the mast cell releases granules containing histamine and other 
mediators of inflammation such as platelet activating factor (PAF) from, TNF 
alpha, IL-3, IL-4, IL-5, IL-6, IL-8, IL-13, GM-CSF, PGD-2, and leukotrienes (LTC4, 
LTD4, LTEA). Histamine, TNF alpha, and IL-8 also stimulate endothelial adhesion 
molecules that favors the migration of eosinophils, monocytes, and neutrophils 
from the bloodstream to the skin.
Histamine is an amine vasoactive located in granules of mast cells [6], baso-
phils, and platelets. Its effects on the skin are mediated through histamine H1 
and H2 receptors. H1 receptors mediate urticaria vasodilation, increased vascular 
permeability, and sensory nerve stimulation. Sensory nerve stimulation deter-
mines the release of neuropeptides such as substance P, peptide vasoactive intes-
tinal (VIP), and somatostatin, which in turn induce the mast cell activation and 
increase in histamine.
Figure 6. 
Angioedema.
Figure 7. 
Angioedema.
Yogurt Soured cream
Buttermilk Quark
Cottage cheese Alcohol
Hard cheeses, cheddar Vinegar
Aged cheeses, brie Sauerkraut
Table 1. 
Histamine liberator food.
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The vascular endothelium expressed a significant number of H2 receptors, so 
the vascular response in the UC is an immunomodulatory effect, to increase the 
synthesis of pro-inflammatory cytokines such as IL-1 and IL-6 of monocytes and 
IL-6 and IL-8 cell endothelial. In addition to histamine, other soluble factors syn-
thesized by mast cells contribute to the increase of vascular dilation and permeabil-
ity; favor chemotaxis, cell activation of leukocyte, and endothelial cells; and induce 
stimulation sensory. These are the cytokines, chemokines, and neuropeptides and 
arachidonic acid metabolites.
The degranulation is attributed to immunological causes (autoimmune, IgE-
dependent, immune complexes, complement-dependent), not immune (pseudo-
allergies, agents release by mast cells) and idiopathic. The path of the synthesis 
of prostaglandins and leukotrienes, hours later the mast cell activation, occurs 
in the synthesis of leukotrienes and prostaglandins from arachidonic acid via 
two-way enzymatic metabolism: the cyclooxygenase path and the lipoxygenase 
pathways.
Studies have shown that LTB4 has a potent chemotactic activity, which is pro-
duced by mast cells in the early and selective recruitment of leukocytes. At chronic 
urticaria (CU), these mediators appear to be the most important in the chronicity of 
the disease. There are no immune reactions (pseudoallergics); the mechanisms are 
not clear but may compromise the metabolism of arachidonic acid, prostaglandins, 
and leukotrienes [3] (Figure 8).
Citrus fruit Chocolate
Papaya Fish
Strawberries Crustaceans
Pineapple Pork
Nuts Egg white
Peanuts Additives
Tomatoes Liquorice
Spinach Spices
Table 2. 
Foods as being capable of releasing endogenous histamine.
Figure 8. 
Physiopathology of urticaria. Note like that the mast cells are the principal cells implicated.
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3. Classification
According to the time evolution, urticaria can be divided into:
• Acute urticaria: less than 6 weeks.
• Chronic urticaria*: lesions appear for more than 6 weeks [7].
Recurrent urticaria: outbreaks recur over time, but its duration is limited. 
Episodes of hives last less than asymptomatic intervals.
* Chronic urticaria is divided into two:
Spontaneous chronic urticaria: spontaneous emergence of hives, angioedema, or 
both for longer than 6 weeks, due to a known or unknown cause.
Inducible urticaria: physical urticarial (This hives occur at the site of the stimu-
lation)l, cholinergic, aquagenic and contact urticarias (Figure 9).
4. Symptomatology
Urticaria typically presents well circumscribed wheals (polimorphyc, serpengi-
nous or round), with intensely pruritic for less than 24 hours of evolution. Wheals 
can be generalized, including arms, legs, face. Urticaria +/− angioedema (primar-
ily in the face), can be acute (with an evolution of less than 6 weeks), or chronic 
(greater than 6 weeks [8] (Figures 10–15).
5. Diagnosis
For diagnosis we have several tools, among which the most useful, simple, and 
cost-effective is the clinical history, but we can ask for additional tests in the case of 
diagnostic doubt or suspicion of systemic disease [2].
5.1 Clinical history
A detailed clinical history and a good physical examination of the patient are 
necessary to make the diagnosis.
Figure 9. 
Acute and chronic urticaria.
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Thanks to its history, we can classify chronic urticaria as spontaneous or inducible. 
For this, we must focus on the following aspects:
• A family history of atopy or urticaria.
• Commonly used drugs and relation with the hives.
Figure 10. 
Generalities of urticaria.
Figure 11. 
Dermatological manifestations of urticaria. Note the typical hives.
Figure 12. 
Dermatological manifestations of urticaria. Note the erythema.
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• A history of allergies, infections, or any other cause that has been able to trigger 
hives.
• Work performed and hobbies.
• Induction of urticaria due to exercise or exposure to physical agents.
• How the body reacts to insect bites.
• If the patient has been on holidays or trip recently.
• If it has relationship with the menstrual cycle or stress.
• If the quality of life is affected.
• Duration of the disease.
• Frequency and duration of the hives, size, shape, and distribution.
• If associated symptoms are subjective such as pain, burning, etc.
• If the patient has nocturnal or diurnal variation.
• How the response was to the treatments used.
5.2 Complementary tests
Complementary tests serve as support to the diagnosis, to detect associated 
systemic diseases or for differential diagnosis.
Basic laboratory tests, as blood count and biochemical reaction (determination 
of C-reactive protein, glomerular sedimentation rate), can help us rule out there is a 
systemic disease. The baseline of tryptase, antithyroid antibodies, and thyroid pro-
file and study of complement and specific IgE where allergy is suspected, could also 
be useful. If an infection cause is suspected, hepatitis B and C virus or Helicobacter 
Pylori could be detected.
New guidelines recommend not to perform additional exploration in a 
systematic way in acute urticaria and just a complete blood count with ESR and 
a suspension of nonsteroidal anti-inflammatory drugs (NSAIDs) in the CU 
(Figure 16).
Figure 13. 
Linear hives made by compression.
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Figure 16. 
Diagnosis algorithm.
Figure 15. 
Urticaria and angioedema.
Figure 14. 
Coalescing urticarial papules.
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6. Treatment
Different ways are approached for the treatment of urticaria: eliminating his-
taminergic food such as seafoods, canned goods, tomatoes, strawberries, bananas, 
pineapple, or apples and avoiding nonsteroidal anti-inflammatory drugs (NSAIDs) 
[9], nonsedative H1-antihistamines, and in severe cases systemic corticosteroids [10].
6.1 Mild forms of urticaria
• The treatment of choice are antihistamines, from a daily tablet up to four 
tablets as maximum dose.
• Corticosteroids are excluded for exacerbations and must be prescribed in short 
guideline (maximum 10 days) without progressive decrease.
• Avoid taking NSAIDs.
6.2 Severe forms of urticaria or exacerbations and associated angioedema
• Nonsedative H1-antihistamines to full dose (four tablets in a day) [11].
• Systemic corticoids, preferably in short treatment (10-day short guideline).
• Forms resistant to treatment: biological agents (omalizumab*).
• Avoid taking NSAIDs (Figure 17).
*Omalizumab is a recombinant humanized monoclonal antibody, which 
blocks the high-affinity Fc receptor of IgE (Figure 18). It has been approved for 
treatment in cases of moderate-to-severe asthma, but it has promising results 
in the management also of chronic urticaria [12]. The dose is 150 or 300 mg by 
subcutaneous injection every 4 weeks. Dosing is not dependent on body weight 
or serum IgE level. The appropriate duration for CIU has not been evaluated yet. 
It’s necessary to periodically reassess the need for continued therapy with omali-
zumab [13].
6.2.1 Clinical guidelines
The European Academy of Allergy and Clinical Immunology (EAACI)/Global 
Allergy and Asthma European Network (GA2LEN)/European Dermatology 
Forum (EDF)/World Allergy Organization (WAO) and the American Academy 
of Allergy, Asthma, and Immunology (AAAAI) have some differences in their 
recommendations for urticaria treatment, but the core recommendations remain 
similar.
A brief summary of AAAAI guidelines are as follows [14]:
As first-line treatment, second-generation nonsedating H1 antihistamines.
Remain in the treatment algorithm first-generation H 1 antihistamines (differs 
from EAACI/GA 2LEN/EDF/WAO guidelines).
Second-line options to consider: adding other second-generation H 1 antihis-
tamines, up-dosing second-generation H 1 antihistamines, leukotriene receptor 
Primary Care
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antagonists, adding H 2 antagonists or first-generation H 1 antihistamines at 
bedtime.
Omalizumab as third-line treatment.
Corticosteroids considered only for short treatment.
Cyclosporine A* is used in refractory chronic urticaria not responsive to other 
treatments.
A brief summary of EAACI/GA2LEN/EDF/WAO guidelines are as follows:
First-line treatment, second-generation H 1 antihistamines.
Up-dosing second-generation H1 antihistamines are the second-line therapy.
Omalizumab is the third-line treatment, which is recommended because it is less 
toxic than cyclosporine A.
Figure 18. 
Monoclonal antibody that binds to the Cε3 domain of circulating IgE, which prevents IgE from binding to and 
activating receptors in mast cells (Figure 19).
Figure 17. 
Nonsedative antihistamines.
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Not included in algorithm H2 antihistamines (used only on an individual case).
Avoid first-generation H1 antihistamines based on benefit to risk ratio.
Corticosteroids may be considered only for the short-term intervention.
Cyclosporine A for refractory chronic urticaria not responsive to other 
treatments.
*Cyclosporin A is an immunosuppressive agent, widely used in organ transplan-
tation to prevent rejection.
The current version of the EAACI/GA2LEN/EDF/WAO urticaria guideline 
recommends:
When chronic inducible urticaria is suspected, differential diagnoses should 
be ruled out. The diagnosis should be confirmed by provocation test disease.  
The activity should be measured by determining the trigger threshold disease 
burden and control should be measured.
Second-generation H1 antihistamines remain the treatment of first choice.
If continuous treatment for 2–4 weeks does not lead to adequate control of 
symptoms, the guidelines recommend up-dosing (up to four times the standard 
dose).
If there is no improvement with high-dose antihistamines, it is recom-
mended to add omalizumab to the regimen in patients with chronic spontaneous 
urticaria.
If there is no success after 6 months of omalizumab therapy, off-label treatment 
with cyclosporine is recommended.
7. Assessment scales
Assessment scales serve to evaluate the treatment, as well as this pathological 
entity affects the quality of life of the patient. We have the urticarial activity score 
(UAS) [15] or angioedema activity score (AAS) [16], chronic urticaria quality-of-
life questionnaire, and urticaria control test (UCT).
Figure 19. 
Recommended treatment algorithm for chronic urticaria.
Primary Care
14
The current guideline endorses the urticaria activity score and/or the 
angioedema activity score to assess the disease activity in CSU patients [17] 
(Figure 20).
The urticaria control test should be used in all CSU patients. The UCT is a 
retrospective tool used to rapidly and reliably assess disease control with four 
simple questions (Figure 21). Patients answer each of the four UCT questions, and 
the corresponding points (0–4 per answer) are added up to yield a total score of 
0–16. The cutoff for controlled urticaria is 12 points. A score of 11 or less indicates 
insufficient disease control, whereas a score of 12 or more suggests adequate disease 
control [18].
Conflict of interest
None.
Figure 20. 
UAS.
Figure 21. 
Urticaria control test.
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